<italic toggle="yes">Bundibugyo ebolavirus</italic> Survival Is Associated with Early Activation of Adaptive Immunity and Reduced Myeloid-Derived Suppressor Cell Signaling

par Courtney Woolsey, Viktoriya Borisevich, Krystle N. Agans, Karla A. Fenton, Robert W. Cross, Thomas W. Geisbert
Publié 2021

Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever

par Sergio E. Rodriguez, Robert W. Cross, Karla A. Fenton, Dennis A. Bente, Chad E. Mire, Thomas W. Geisbert
Publié 2019

Single dose rVSVΔG-JUNVGP vaccine protects guinea pigs against lethal Junin virus challenge

par Teresa E. Sorvillo, Robert W. Cross, Dylan M. Johnson, Natalie S. Dobias, Karla A. Fenton, Chad E. Mire, Thomas W. Geisbert
Publié 2021

Rational design of universal immunotherapy for TfR1-tropic arenaviruses

par Hadas Cohen-Dvashi, Ron Amon, Krystle N. Agans, Robert W. Cross, Aliza Borenstein-Katz, Mathieu Mateo, Sylvain Baize, Vered Padler-Karavani, Thomas W. Geisbert, Ron Diskin
Publié 2020

A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus

par Thomas W. Geisbert, Kathryn Bobb, Viktoriya Borisevich, Joan B. Geisbert, Krystle N. Agans, Robert W. Cross, Abhishek N. Prasad, Karla A. Fenton, Hao Yu, Timothy R. Fouts, Christopher C. Broder, Antony S. Dimitrov
Publié 2021

Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment

par Robert W. Cross, Zachary A. Bornholdt, Abhishek N. Prasad, Joan B. Geisbert, Viktoriya Borisevich, Krystle N. Agans, Daniel J. Deer, Kevin Melody, Karla A. Fenton, Heinz Feldmann, Armand Sprecher, Larry Zeitlin, Thomas W. Geisbert
Publié 2020

Combination therapy protects macaques against advanced Marburg virus disease

par Robert W. Cross, Zachary A. Bornholdt, Abhishek N. Prasad, Viktoriya Borisevich, Krystle N. Agans, Daniel J. Deer, Dafna M. Abelson, Do H. Kim, William S. Shestowsky, Lioudmila A. Campbell, Elaine Bunyan, Joan B. Geisbert, Karla A. Fenton, Larry Zeitlin, Danielle P. Porter, Thomas W. Geisbert
Publié 2021

Development of a SARS-CoV-2 Vaccine Candidate Using Plant-Based Manufacturing and a Tobacco Mosaic Virus-like Nano-Particle

par Joshua M. Royal, Carrie A. Simpson, Alison A. McCormick, Amanda Phillips, Steve Hume, Josh Morton, John Shepherd, Youngjun Oh, Kelsi Swope, Jennifer L. DeBeauchamp, Richard J. Webby, Robert W. Cross, Viktoriya Borisevich, Thomas W. Geisbert, Jennifer K. Demarco, Barry Bratcher, Hugh Haydon, Gregory P. Pogue
Publié 2021

Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits

par James E. Robinson, Kathryn M. Hastie, Robert W. Cross, Rachael E. Yenni, Deborah H. Elliott, Julie A. Rouelle, Chandrika B. Kannadka, Ashley A. Smira, Courtney E. Garry, Benjamin T. Bradley, Haini Yu, Jeffrey G. Shaffer, Matt L. Boisen, Jessica N. Hartnett, Michelle A. Zandonatti, Megan M. Rowland, Megan L. Heinrich, Luis Martínez-Sobrido, Benson Cheng, Juan C. de la Torre, Kristian G. Andersen, Augustine Goba, Mambu Momoh, Mohamed Fullah, Michael Gbakie, Lansana Kanneh, Veronica J. Koroma, Richard Fonnie, Simbirie C. Jalloh, Brima Kargbo, Mohamed A. Vandi, Momoh Gbetuwa, Odia Ikponmwosa, Danny A. Asogun, Peter O. Okokhere, Onikepe A. Follarin, John S. Schieffelin, Kelly R. Pitts, Joan B. Geisbert, Peter C. Kulakoski, Russell B. Wilson, Christian T. Happi, Pardis C. Sabeti, Sahr M. Gevao, S. Humarr Khan, Donald S. Grant, Thomas W. Geisbert, Erica Ollmann Saphire, Luis M. Branco, Robert F. Garry
Publié 2016